As EXCITE International grows, we continue to strengthen our relationships with global strategic partners who represent regulators, payers, health systems, patients, expert end-users and scientists (“stakeholders”). Through this global partnership, EXCITE International offers companies and its stakeholders an unparalleled collaborative approach to selecting, evaluating and adopting impactful new health technologies across the full continuum from proof-of-concept to protocol development.
Our unique approach meets the expectations of multiple stakeholder strategic partners. Additionally, the organization has the infrastructure to successfully conduct clinical trials involving Clinical Research Organizations, as well as academic and health system clinical trials networks. This comprehensive alignment along with the involvement of strategic stakeholders accelerates and de-risks the pathway to adoption by pulling rather than pushing new technologies into health systems. EXCITE International is one of the largest, most important and boldest initiatives of its kind ever assembled. While the early and ongoing involvement of strategic stakeholders in our offerings is designed to support the final application for adoption, coverage and payment is ultimately under the purview of each health system/payer.
We have built strong relationships with payers and health systems whose pivotal involvement occurs through active participation on the Payers’ Advisory Committee . Representatives on the Payers’ Advisory Committee are drawn from Blue Cross Blue Shield Association, Centre for Medicare and Medicaid, Kaiser Permanente and AETNA.
Industry is also well represented through our close association with AdvaMed and the Medical Devices Manufacturers Association (MDMA). Our close working relationship with the Medical Devices Innovation Consortium (MDIC) focuses on regulatory science and discussions have been initiated with the Yale Medical School CORE program and the Patient Centered Research Foundation to develop access patient outcomes data for technology evaluation purposes. Currently, we are in early discussions to develop similar opportunities with Evidence Street (Blue Cross Blue Shield Association) and the evolving NEST program (MDIC). We include the expectations of the FDA in all our offerings through the interaction between the FDA and companies to define the most appropriate pathway to regulatory approval.
An early version of the EXCITE concept was initially piloted in Ontario starting in 2012 with funding from the Ontario government. The current and more advanced EXCITE International model includes an impressive functional cross section of stakeholders.
In 2018, EXCITE International established a formal relationship with Norway through an MOU with Norway HealthTech with the intent to expand into a national collaboration, EXCITE Norway. The idea is to extend the partnership through the development of a Nordic Collaboration built on the foundation of this initiative.
In 2018, EXCITE International established a formal relationship with the Netherlands through an agreement with Radboud University Medical Center (Radboudumc). The vision will develop this relationship into a national collaboration, EXCITE Netherlands. There are three key Radboudumc programs that are integral to the partnership:
Over the past two years, there has been considerable involvement between EXCITE International and the National Health Service (NHS), NICE, senior investigators, the Association of British HealthTech Industries, the Office of Life Sciences, the Academic Health Science Networks, and the IDEAL program. This engagement is reflected in the strong representation of the United Kingdom on key EXCITE International Board subcommittees. EXCITE International will continue to work with the appropriate interface with the U.K.’s national strategy to accelerate the adoption of new health technologies as the opportunity to formalize the relationship according to our mandate to encourage global reach for member countries.